UNCY – unicycive therapeutics, inc. (US:NASDAQ)

News

Unicycive Therapeutics (NASDAQ:UNCY) had its "buy" rating reaffirmed by analysts at Guggenheim.
Unicycive resubmits NDA for hyperphosphatemia asset [Seeking Alpha]
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth [Yahoo! Finance]
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) [Yahoo! Finance]
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com